Immuno-Oncology

The FDA granted a priority review to durvalumab in October for the treatment of patients with stage III, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation.

Jonathan Ledermann, MD, discusses the promise of immunotherapy in ovarian cancer and emphasized the importance of participation in clinical trials.

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.

The addition of atezolizumab to bevacizumab, carboplatin, and paclitaxel delayed progression or death compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.

Maria De Santis, MD, discusses the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.

Andrea Necchi, MD, discusses the evolution of bladder cancer therapies, the challenge with the currently available agents, and the next steps and clinical trials being conducted in the field.

An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.

A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.

Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.

Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Tanya B. Dorff, MD, associate professor of clinical medicine, University of Southern California, discusses current agents available for patients with metastatic castration-resistant prostate cancer (mCRPC).